ASCO 2020：11项中国研究被选为口头报告，17项Poster报告

受在世界上新的冠疫情阻碍，原定于5年初29日~6年初2日在芝加哥举行的美国临床研习（ASCO）大会来年将首次以终点站上形式举办，这是目前最大规模的终点站上盛会。今天，联席会议的概要题目公布，合共103个sessions，西方合共有11项分析跻身口头报告，17项跻身Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨用做HER2+前列腺腺癌乳腺腺癌（PHOEBE）：一项III期随机检验。

首站：前列腺腺癌乳腺腺癌

所写：西方医学科学院所医院徐兵河讲师、马飞讲师，复旦大学另有所医院胡夕春讲师等

概要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可切除三阴性乳腺腺癌标准外科切除后卡培他滨维持节拍化学疗法的III期检验（SYSUCC-001）。

首站：乳腺腺癌—局部/区域/常规外科切除

所写：里文系传染病里心称王树森讲师等

概要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用前列腺腺癌脑干的表型特征来预测脑干脊液里可逆DNA探测的概率: 新的机器对抗从前对手

首站：新的机器彻底解决从前解决办法

所写：徐美芹 徐德兰等

概要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对科特迪瓦拉非尼作为末期大肠巨噬细胞腺癌的一终点站外科切除：一项开放关键字、随机、多里心II/III期检验。

首站：上皮巨噬细胞腺癌—肺食管、胰腺和实为

所写：四川大学华西所医院毕锋讲师、西方人民解放军八一所医院秦叔逵讲师等

概要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

西方末期大肠腺癌患儿阿帕替尼二终点站外科切除：一项随机、口服比对、双盲III期分析

首站：上皮巨噬细胞腺癌—肺食管、胰腺和实为

所写：西方人民解放军八一所医院秦叔逵讲师、四川大学华西所医院徐秋讲师等

概要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

末期病情恶化性卵巢腺癌二次巨噬细胞减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

专题：外科腺前列腺癌

所写：复旦大学另有里山所医院臧荣余讲师等

概要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腺癌根治性子宫切除术后常规外科切除里的序贯放化学疗法对比基本上放疗或同步放化学疗法（STARS分析）：一项随机、比对、开放关键字的III期检验。

联席会议：外科腺前列腺癌

所写：里文系传染病里心大白讲师、刘继红讲师等

概要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比化学疗法用做可切除的EGFR等位基因的N1-N2期NSCLC-随机III期动物模型的最终总体生存分析。

专题：肺腺癌—非小巨噬细胞局部-区域/小巨噬细胞/其他腿部

所写：广东省人民所医院吴一龙讲师等

概要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因若无移出非小巨噬细胞肺腺癌患儿一终点站酪氨酸趋化因子药物合组或不合组积极的部队局部放疗：III期开放关键字临床随机检验（SINDAS）的里期结果（NCT02893332）。

专题：肺腺癌-非小巨噬细胞移出

所写：四川省人民所医院曾铭讲师等

概要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类死亡-1（PD-1）的人源化IgG4单克隆抗体合组阿昔替尼用做前列腺腺癌呼吸道卵巢癌患儿的Ib期分析的总生存期和人类遥相呼应分析。

专题：卵巢癌/皮肤腺癌

所写：北京大学所医院郭军、盛锡楠讲师等

概要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：非标准CAR-T巨噬细胞首次人体检验外科切除病情恶化/难治性T巨噬细胞急性红巨噬细胞肺癌（r/r T-ALL）的实用性和。联席会议：研发里的外科切除技术-免疫外科切除。所写：称顾明欣等概要：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在末期食管点状巨噬细胞腺癌患儿里的应用：一项随机的开放关键字II期检验（ORIENT-2）。联席会议：上皮巨噬细胞腺癌-肺食管腺癌、胰腺腺癌和实为道腺癌所写：徐建明讲师等概要：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D选择性CAR-T巨噬细胞对髓母巨噬细胞瘤的根除性外科切除联席会议：里枢神经系统所写：代红久、孙斌、杨东、徐晖、顾华以、魏佳、赵旭东概要：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在末期错配修复有缺陷患儿里的应用联席会议：研发里的外科切除学-免疫外科切除所写：沈琳讲师等概要：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨髓CD7-CART外科切除病情恶化/难治性ACUTE红巨噬细胞肺癌/乳腺癌的首例人体动物模型联席会议: 研发性外科切除学-免疫外科切除所写简介：张明志，南部县等概要：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组应用做末期实质上瘤患儿的Ib期分析联席会议：发展性外科切除学--分子靶向类固醇和人类科学所写：龚继芳，沈琳讲师等概要：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组紫杉醇和nedaplatin外科切除病情恶化性或前列腺腺癌食管点状巨噬细胞腺癌（ESCC）患儿的II期分析。联席会议：上皮巨噬细胞腺癌-肺食管、胰腺和实为道腺癌的分析所写：称王志极强，徐玉红，称王德申，称王凤华，任超，谭琼 称王志极强、徐玉红、称王德深、称王凤华、任超、谭琼概要：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.联席会议：上皮巨噬细胞腺癌-肺食管腺癌、胰腺腺癌和实为管腺癌的二终点站外科切除所写：宋艳等概要：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体放射状RNA分类器用做初始活检时探测高等级腺癌的尿液外体放射状RNA分类器：一项多里心的回顾性分析联席会议：泌尿输卵管腺前列腺癌--腺癌、睾丸腺癌和腺癌所写简介：Liaoyuan Li等概要：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 局部末期宫颈腺癌并发化学疗法后的常规化学疗法联席会议: 外科腺前列腺癌所写简介： 徐珉珉等概要：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼外科切除甲状腺髓性腺癌的相关性：基于ALTER01031检验的分析。会话：外周所写：唐山市所医院用心讲师概要：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、形状和成年人对安洛替尼外科切除后患儿结局的阻碍: ALTER01031的亚组分析联席会议：外周所写：唐山市所医院用心讲师概要：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析预测I-IIIA期非小巨噬细胞肺腺癌（NSCLC）患儿术后病情恶化: GASTO1035和GASTO1018的结果联席会议：肺腺癌-非小巨噬细胞局部-区域性/小巨噬细胞/小巨噬细胞/其他胸科腺前列腺癌所写：Si-Yu Wang等概要：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺腺癌（NSCLC）里EGFR酪氨酸趋化因子药物的新的型耐药机制联席会议:肺腺癌-非小巨噬细胞前列腺腺癌肺腺癌所写简介：赵昕，金玲玲，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、华宝、薛武、杨绍、范敏概要：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验里末期卵巢癌总生存的替代终点联席会议：卵巢癌/皮肤腺癌所写：聂润聪，袁书极强，徐元芳，陈英波，周志伟 聂润聪、袁书极强、徐元芳、陈英波、周志伟概要：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼外科切除病情恶化或前列腺腺癌原发性恶性骨患儿的II期分析联席会议： 肺癌所写：唐丽娜，牛晓辉，称王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称王振、蔡启庆、涂崇奇、范正福、杨瑶概要：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在末期肺癌患儿多终点站外科切除里的实用性和。联席会议：肺癌所写：姚伟涛，称王家极强，张瑞，称顾明，杜新的辉，田志浩，牛晓颖 姚伟涛、称王家极强、张瑞、称王鑫、杜鑫辉、田志超、牛晓英概要：11526广告：414